Skip to content

To study the effect and mechanism of gut microbiota and its metabolites, SNPS associated with coronary heart disease and estrogen on coronary microvascular disease

To study the effect and mechanism of gut microbiota and its metabolites, SNPS associated with coronary heart disease and estrogen on coronary microvascular disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100702
Enrollment
Unknown
Registered
2025-04-14
Start date
2022-08-15
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary microvascular disease

Interventions

MECAS without ischemia combined with CMVD group:None
MECAS without ischemia group:None
MECAS ischemia combined with CMVD group:None
Simple MECAS ischemia group:None
Simple CMVD group:None
Healthy control group:None

Sponsors

Southwest Hospital, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients admitted to the cardiovascular Department of Southwest Hospital who were preliminarily evaluated as suspected myocardial ischemia 2)Provision of signed and dated informed consent form

Exclusion criteria

Exclusion criteria: 1) Age<18 years 2) Intolerance to adenosine 3) Ultrasonic cardiogram LVEF<50% 4) Severe valvular heart disease (more than moderate stenosis and/or insufficiency) 5) Severe hepatic or renal insufficiency (elevated aminotransferase more than 3 times the normal value, estimated glomerular filtration rate <30 mL/min/m2); 6) Severe cardiac insufficiency (NYHA grade =3 or KILLIP grade =2) 7) Acute myocardial infarction 8) Tumors and autoimmune diseases 9) Contraindications of exercise stress test (severe tachyarrhythmia, hypertrophic obstructive cardiomyopathy, etc.); 10) Pregnancy or lactation 11) Life expectancy <1 year 12) Previous history of gastrointestinal surgery 13) History of antibiotic use in the past 2 months 14) History of probiotics use in the past 1 month 15) Abdominal pain, diarrhea and other gastrointestinal symptoms in the past 1 month 16) Patients who used antacids, bismuth, tannic acid, medicinal charcoal, or tincture daily in the past 2 weeks

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular events, MACE;

Secondary

MeasureTime frame
Assessment OF symptom;Cognitive function;

Countries

China

Contacts

Public ContactZhihui Zhang

Southwest Hospital, Army Medical University

xyzpj@126.com+86 136 1761 6980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026